An FDA listing anomaly: a Hybio liraglutide pen is recorded as marketed six months before its application was approved

A liraglutide pen made by Hybio Pharmaceutical carries a marketing start date of June 21, 2024, in the FDA's public drug listing directory, even though the application covering that product, ANDA215503, was not approved by the FDA until December 23, 2024 ^[1][2]. The mismatch is a listing-record anomaly. It is not evidence that a true ANDA-approved generic version of liraglutide was sold in the United States six months before the FDA cleared it.

Drugs@FDA, the agency's official database of drug approvals, records ANDA215503 as approved on December 23, 2024, with Hikma listed as the applicant ^[2]. Hybio's own two-pen and three-pen carton listings tied to that same application show marketing start dates of December 24, 2024, one day after approval, which lines up with the standard sequence of approval followed shortly by product launch ^[2]. The single-pen listing dated June 21, 2024, breaks that pattern by six months, and nothing in the sources explains why.

Liraglutide is the active ingredient in Novo Nordisk's brand-name drugs Victoza and Saxenda ^[1]. Victoza, approved as NDA022341, has been sold in the US since January 2010, and Saxenda since late 2014 ^[1]. Generic competition arrived far more recently. According to the source material, the first generic liraglutide a US patient could actually buy was an authorized generic marketed by Teva, which reached the market on June 24, 2024 ^[1]. An authorized generic is made using the same manufacturing process as the brand-name drug but sold under a generic label, and it does not require its own separate ANDA approval in the way a typical generic does.

Other liraglutide generics have followed a more conventional path. Biocon Pharma's ANDA215245 was approved on March 11, 2026, according to Drugs@FDA submission records ^[2]. Meitheal Pharmaceuticals' ANDA218115 shows a marketing start date of April 2, 2025 ^[1]. Teva also has a separately numbered ANDA214568 product with a marketing start date of August 28, 2025 ^[1]. These varied dates show that liraglutide generics have entered the market in stages over roughly two years, not all at once.

Why it matters for patients

For most patients, this specific listing error changes nothing about what is actually available at a pharmacy. The FDA's own approval database, Drugs@FDA, is the authoritative record of when a drug was legally cleared for sale, and it places Hybio's approval in December 2024, not June ^[2]. Patients checking whether a generic drug is real and approved should rely on that approval record rather than the marketing-start-date field in the separate NDC directory, which is self-reported by manufacturers and can contain errors ^[1][2].

The broader point for anyone following liraglutide generics is that supply has arrived unevenly. Teva's authorized generic was first, landing in June 2024 ^[1]. Other companies' true ANDA generics, including those from Hybio, Biocon, and Meitheal, followed on their own separate timelines stretching into 2025 and 2026 ^[1][2]. That staggered rollout can affect which generic version a pharmacy stocks and when a lower-cost option becomes available in a given market.

What happens next

The sources do not say whether the FDA or Hybio has corrected or explained the June 21, 2024 listing date. It is not yet known whether this reflects a data-entry mistake, a listing tied to a different regulatory pathway, or something else. Patients and pharmacists relying on NDC directory dates for this specific product should be aware the field may not be reliable until it is corrected ^[1][2].